Morgan Stanley Trims Disc Medicine (NASDAQ:IRON) Target Price to $40.00

Disc Medicine (NASDAQ:IRON – Get Free Report) had its price objective cut by Morgan Stanley from $75.00 to $40.00 in a research note issued on Tuesday, Benzinga reports. The firm presently has an “equal weight” rating on the stock. Morgan Stanley’s target price suggests a potential upside of 26.78% from the stock’s previous close. A […]

Related Keywords

Kevin Bitterman ,Stifel Nicolaus ,Raymond James ,Renaissance Technologies ,Citigroup Inc ,Venture Fund Xlp Atlas ,Geode Capital Management ,Securities Exchange Commission ,Disc Medicine Inc ,Morgan Stanley ,Millennium Management ,Disc Medicine ,Get Free Report ,Medicine Trading Down ,Director Kevin Bitterman ,Exchange Commission ,Venture Fund ,Capital Management ,Point Capital Management ,Disc Medicine Daily ,Nasdaq Iron ,Iron ,Medical ,Lower Price Target ,